<dd id="yfl9j"><noscript id="yfl9j"></noscript></dd>

    <rp id="yfl9j"><acronym id="yfl9j"></acronym></rp><progress id="yfl9j"><pre id="yfl9j"></pre></progress>
      <rp id="yfl9j"></rp>
            1. <rp id="yfl9j"><acronym id="yfl9j"></acronym></rp>

                  1. <rp id="yfl9j"><object id="yfl9j"><input id="yfl9j"></input></object></rp>
                      <button id="yfl9j"></button><button id="yfl9j"><acronym id="yfl9j"></acronym></button>
                    1. <tbody id="yfl9j"></tbody>
                    2. <tbody id="yfl9j"></tbody>
                      <em id="yfl9j"><acronym id="yfl9j"></acronym></em>

                    3. Artificial heart valves and transcather implantation systems
                      The product which is interventive, minimally invasive, without surgical sutures and cardiopulmonary bypass is used to replace the diseased mitral valve. This new designed product can simplify the replacement surgery, significantly reducing the risks of treatment and increasing success rate. Moreover, this can shorten patients’ postoperative recovery time and cut down costs. Furthermore, reduced price of similar products enables more patients to have opportunities to endure risk and expense of surgery and treatment. As a revolutionary treatment, transcatheter artificial heart valve prosthesis is being well recognized by experts. In the future, clinical demands will grow explosively.
                      人工心臟瓣膜及導管植入系統具有介入、無手術縫線、無需體外循環和無須開胸手術等特點,用于置換心臟內病變的二尖瓣瓣膜。 這種新型產品將使心臟瓣膜置換手術過程簡化、治療風險大幅降低、成功率將顯著提高,同時也將縮短病人術后恢復時間及大大降低費用,拉低進口同類產品價格,使更多的病人能夠承受手術的風險和費用而得到治療。 介入人工心臟瓣膜作為一種革命性的治療手段,正日益被專家所認同,在可預見的未來幾年內,臨床需求將會呈現爆發性的增長。
                      无遮挡很爽很污很黄的网站 gogo国模啪啪人体| 中文字幕乱码亚洲影视| 在线不卡av片免费观看| 午夜神器a片免费看| 国产熟睡乱子伦视频在线观看| 娇小6一8xxxxx| 午夜18禁试看120秒男女啪啪| 成年女人看片免费视频播放人| 一 级 黄 色 片| a毛片免费全部播放完整| 欧美a级中文完在线看完整版|